This article has Open Peer Review reports available.
Choroidal metastases in testicular choriocarcinoma, successful treatment with chemo- and radiotherapy: a case report
© Guber et al; licensee BioMed Central Ltd. 2011
Received: 30 August 2011
Accepted: 7 December 2011
Published: 7 December 2011
Choriocarcinoma is a very rare cause of ocular metastasis. Only 18 male patients have been reported on, 4 of whom survived, but with significant loss of vision.
A 26-year-old Caucasian man, suffering from testicular choriocarcinoma with pulmonary, cerebral, renal, hepatic and osseous metastases, underwent left radical orchiectomy. While being treated with chemotherapy, he presented with loss of vision in the left eye. Ophthalmoscopy revealed bilateral non-pigmented, hemorrhagic choroidal tumours, compatible with secondary lesions. Continued chemotherapy and stereotactic radiotherapy of the skull and spine lead to full remission with excellent vision, after more than 4 years of follow up.
Testicular choriocarcinoma is an exceptional cause of choroidal metastasis, potentially asymptomatic and with specific clinical features. Radiotherapy can complement radical orchiectomy and chemotherapy, to achieve full remission and maintain good vision.
Intraocular metastases are present in up to 10% of patients with systemic malignancies . With tumour cells spreading hematogenously, the posterior choroid is frequently involved because of its rich vasculature . In females, the most common primary site is the breast, whereas, in males, it is the lung.
Choriocarcinoma is a highly malignant metastatic tumour, derived from undifferentiated placental trophoblasts ('gestational choriocarcinoma') or from non-placental totipotent cells, present in the testis, the ovary or the pineal gland ('non gestational choriocarcinoma'). It is characterized by the large amounts of chorionic gonadotropin produced.
Choriocarcinoma is a rare cause of choroidal metastasis. Only 18 male patients have been reported on, and most of them had a poor prognosis [2–4]. We present a man who developed bilateral choroidal metastases from a testicular choriocarcinoma under chemotherapy. The ocular tumours regressed following irradiation. Four years later, he is in remission and has excellent vision.
A 26-year-old man was referred to the Jules-Gonin Eye Hospital with loss of vision and a non-pigmented tumour in his left eye. In the previous two weeks, he had been diagnosed with a left testicular tumour and multiple metastases to the lung, brain, cerebellum, kidney, liver and spine. Histopathology following left radical orchiectomy had revealed a non-seminomatous testicular choriocarcinoma, positive for β-human chorionic gonadotropin (β-HCG) and pancytokeratin, slightly positive for α-fetoprotein (AFP) while negative for carcino-embryonic antigen (CEA). Serum levels were for β-HCG 271 052 U/l (normal < 3.0 U/l)), for AFP 0.9 ng/ml (normal < 10 ng/ml) and for LDH 1757 U/l (normal < 450 U/l). He was receiving chemotherapy with bleomycin, etoposide and cisplatin.
Chemotherapy was continued, with a total of 4 cycles over 3 months' time. Additionally, a stereotactic radiotherapy of the spine and head was performed, the latter including the posterior part of both eyes, using two lateral accelerated photon fields of 6 MV with a total dose of 30.80 Gy in 14 fractions.
We describe a rare case of a patient with bilateral choroidal metastases secondary to testicular choriocarcinoma, successfully treated with chemo- and radiotherapy.
MacDonald described the first case in 1936 . A meta-analysis of the literature in 2006 listed 14 male patients with testicular choriocarcinoma, as well as one with mediastinal and one with retroperitoneal primary choriocarcinoma, metastasizing to the choroids . Since then, 2 more cases of choroidal metastases from testicular choriocarcinoma have been reported [3, 4].
Unlike other metastatic ocular disease, significant haemorrhage is associated with choriocarcinoma metastases in more than 85% of cases and should raise suspicion for this primary [2–4]. Kavanagh suggested a correlation with upregulated levels of vascular endothelial growth factor (VEGF) , thought to be involved in the development of trophoblastic disease .
Prognosis of testicular germ cell tumours -including choriocarcinoma- was poor until the introduction of cisplatin-based chemotherapy in the mid-1970s . Of the 18 male choriocarcinoma patients with choroidal metastases, only 4 were reported to be cured, the first being described in 1999 . Two received only chemotherapy [3, 8], one had a supplementary brain radiotherapy excluding the orbit  and one had 'concurrent radiotherapy to the whole skull and left eye' , though no report specifies the radiation dosage. In our patient, the indication for stereotactic radiotherapy was based on the fact that visual symptoms appeared after chemotherapy had been initiated and that the blood-brain and blood-eye barrier are reputed to be only partially permeable to chemotherapeutics.
Visual acuity of the 4 surviving patients, who all had unilateral choroidal metastases, ranges between CF and 6/12 [3, 7–9]. Our patient, with bilateral metastatic disease, has a visual acuity of 6/6 and 6/9 respectively, despite the parafoveal localization of the left tumour. The coincidentally discovered asymptomatic tumour in the right eye was treated before vision was affected.
We describe a rare case of a patient with testicular choriocarcinoma presenting bilateral choroidal metastases, with specific clinical features and one eye being asymptomatic. Stereotactic radiotherapy of the skull and spine complemented radical orchiectomy and chemotherapy. After more than 4 years of follow up, he is in full remission and has excellent vision.
Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Acknowledgements and funding
- Zografos L, Uffer S, Beati D: Métastases intraoculaires. Tumeurs intraoculaires. Edited by: Zografos L. 2002, Paris: Masson, 381-412.Google Scholar
- Kavanagh MC, Pakala SR, Hollander DA, O'Brian JM: Choriocarcinoma metastatic to the choroid. Br J Ophthalmol. 2006, 90: 650-652. 10.1136/bjo.2005.085829.View ArticlePubMedPubMed CentralGoogle Scholar
- Khurana RN, Di Bernardo C, Handa JT: Improved systemic chemotherapy for metastatic testicular choriocarcinoma can result in excellent prognosis for life and vision. Arch Ophthalmol. 2008, 126: 1008-1009. 10.1001/archopht.126.7.1008.View ArticlePubMedGoogle Scholar
- Dotchin S, Lakosha H, Heathcote JG, Dickinson J: Uveal metastasis from testicular choriocarcinoma presenting as scleritis. Can J Ophthalmol. 2009, 44: 210-211.View ArticlePubMedGoogle Scholar
- MacDonald AE: Choroidal chorionepithelioma secondary to teratoma of the testicle. Arch Ophthalmol. 1936, 16: 672-676. 10.1001/archopht.1936.00840220130013.View ArticleGoogle Scholar
- Bolat F, Haberal N, Tunali N, Aslan E, Bal N, Tuncer I: Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease. Pathol Res Pract. 2010, 206: 19-23. 10.1016/j.prp.2009.07.017.View ArticlePubMedGoogle Scholar
- Zech JC, Subiger L, Chiquet C, Bouvier R, Trepsat C: Testicular choriocarcinoma metastatic to the choroid. Retina. 1999, 19: 164-165. 10.1097/00006982-199902000-00014.View ArticlePubMedGoogle Scholar
- Osada K, Iijima H, Imasawa M, Takahashi H, Kobori Y, Nakagomi H, Takihana Y, Takeda M: Metastatic uveal tumor secondary to testicular choriocarcinoma. Jpn Ophthalmol. 2004, 48: 85-87. 10.1007/s10384-003-0020-4.View ArticleGoogle Scholar
- Nakajima H, Oki M, Matsukura S, Nakamura M, Tokunaga M, Ando K: Germ cell tumors. Case 1. Intraocular metastases from testicular cancer. J Clin Oncol. 2004, 22: 1753-1755. 10.1200/JCO.2004.07.187.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/11/24/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.